|
| Press Releases |
|
 |
|
| Friday, March 24, 2023 |
|
|
医思健康与诺辉健康达成战略合作 共同推动「宫证清」在港上市 |
| 医思健康（2138.HK）与诺辉健康（6606.HK）今日举行签约仪式，双方达成独家战略合作，未来将全面整合双方的优质资源，共同推动宫证清在中国香港的注册上市、分销及市场推广，以居家早筛助力宫颈癌预防医学服务的普及，加速实现宫颈癌的有效预防。 more info >> |
|
|
醫思健康與諾輝健康達成戰略合作 共同推動「宮證清」在港上市 |
| 醫思健康（2138.HK）與諾輝健康（6606.HK）今日舉行簽約儀式，雙方達成獨家戰略合作，未來將全面整合雙方的優質資源，共同推動宮證清在中國香港的註冊上市、分銷及市場推廣，以居家早篩助力宮頸癌預防醫學服務的普及，加速實現宮頸癌的有效預防。 more info >> |
|
|
EC Healthcare Collaborates with New Horizon Health to form Strategic Partnership To Jointly Launch CerviClear in Hong Kong |
| EC Healthcare (2138.HK) and New Horizon Health (6606.HK) host ceremony today to form an exclusive strategic partnership. Both parties will consolidate the resources to empower the launching, distribution, and promotion of CerviClear in Hong Kong. more info >> |
|
| Friday, August 19, 2022 |
|
|
New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82% |
New Horizon Health (6606.HK), China's leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today.
more info >> |
|
| Friday, March 18, 2022 |
|
|
诺辉健康发布2021年报：营收同比增长202%，毛利率攀升至72.7% |
| 中国领先的癌症早筛生物高科技公司诺辉健康（6606.HK）今日发布2021年截至12月31日的年度业绩报告。 more info >> |
|
|
諾輝健康發佈2021年報：營收同比增長202%，毛利率攀升至72.7% |
| 中國領先的癌症早篩生物高科技公司諾輝健康（6606.HK）今日發佈2021年截至12月31日的年度業績報告。 more info >> |
|
| Saturday, August 21, 2021 |
|
|
New Horizon Health Announces 2021 Interim Results: Revenue Increases 317% Year-on-year, Gross Profit Margin Climbs to 56.2% |
| New Horizon Health (6606.HK) (the "Company"), the first public listed cancer screening company in China, has today announced its financial report for the first half year ended 30 June 2021. more info >> |
|
| Friday, August 20, 2021 |
|
|
諾輝健康發佈2021年中報業績：營收同比增長317%，毛利率攀升至56.2% |
| 中國首家專注於癌症早篩的生物高科技公司諾輝健康（6606.HK）今日發佈2021年上半年截至6月30日的財務報告。 more info >> |
|
| Monday, February 8, 2021 |
|
|
基因检测行业的未来明珠获资本巨头鼎力相助 诺辉健康潜力十足 |
| 开年至今，港股市场氛围热烈，康希诺生物、荣昌生物、康方生物等生物科技公司涨势喜人。由于新冠肺炎疫情仍在世界范围扩散，促使医疗需求急剧上升，此类生物科技领域的「18A上市公司」自2020年以来愈发受到市场关注，股价表现亮眼。 more info >> |
|
|
基因檢測行業的未來明珠獲資本巨頭鼎力相助 諾輝健康潛力十足 |
| 開年至今，港股市場氛圍熱烈，康希諾生物、榮昌生物、康方生物等生物科技公司漲勢喜人。由於新冠肺炎疫情仍在世界範圍擴散，促使醫療需求急劇上升，此類生物科技領域的「18A上市公司」自2020年以來愈發受到市場關注，股價表現亮眼。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
雲頂新耀維適平(R)獲中國國家藥品監督管理局批准上市 為中重度潰瘍性結腸炎治療提供新選擇
Feb 6, 2026 14:11 HKT/SGT
|
|
|
云顶新耀维适平(R)获中国国家药品监督管理局批准上市 为中重度溃疡性结肠炎治疗提供新选择
Feb 6, 2026 14:03 HKT/SGT
|
|
|
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025
Feb 6, 2026 13:13 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
